How We Are Unique
Our Modeling Approach
A rigorous fit-for-purpose model development process which quantitatively integrates knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms.
Learn MoreIndustry Experience
Over 100 years of cumulative industry experience spanning the entire therapeutic workflow from early research to clinical pharmacology and regulatory filings.
Learn MoreProprietary Technology
Our modeling process, proprietary technology, and high-performance computing allow us to conduct large-scale simulations quickly and accurately, without having to take unnecessary shortcuts on the biology or the mathematics.
Learn MoreOur Foundations
Mechanistic Modeling
Iterative Collaborations
Interdisciplinary Teams
First-in-Human Dose Predictions
The goal of this collaboration was to develop a QSP model to support translation from preclinical to clinical studies, and first-in-human (FIH) studies and to use this QSP model to provide a deeper understanding of the mechanisms of hUGT1A1-modRNA and to guide design of the first-in-human clinical studies.